November 20, 2012
The Texas Biomedical Research Institute (Texas Biomed) has applied for a patent for a genetically-engineered vaccine for HIV prevention. The vaccine is designed to be administered in a single dose that will last the patient a lifetime. It targets the outer layers of the body structures that first come into contact with the virus. Officials at Texas Biomed believe that the vaccine could be adapted for use against other infections.
Marie-Claire Gauduin, Ph.D., of Texas Biomed's Department of Virology and Immunology is co-inventor on the patent with Philippe Blancou, Ph.D., a visiting scientist from the University of Nice-Sophia Antipolis in France. Gauduin stated that the development of an effective AIDS vaccine that restricts viral replication at the mucosal level of entry may be the best hope of controlling HIV. She added that only life-long stimulation of the immune system by the vaccine will be sufficient to achieve long-term protection.